Payment overview · 2025
General Payments
$470.47
23 reported records · 13 companies
Healthcare provider profile · identity verified
Hugh Michael Oneill, MD
Allopathic & Osteopathic Physicians|Family Medicine · ORLAND PARK, IL · NPI 1578507430
Verified facts
What the public records show
CMS Open Payments records show Hugh Michael Oneill, MD received $470.47 in general payments during 2025 across 23 reported records.
Radius Health, Inc. accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $112.62 | 23.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.71 | 14.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.80 | 9.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $42.73 | 9.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.99 | 8.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.92 | 5.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.62 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.55 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.97 | 4.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.88 | 4.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.39 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.53 | 3.5% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.76 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $470.47 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $112.62 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $69.71 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.71 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $42.73 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.99 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 812 | 233 |
| Metoprolol Succinate | Metoprolol Succinate | 448 | 125 |
| Lisinopril | Lisinopril | 372 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 98 |
| Omeprazole | Omeprazole | 261 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 68 |
| Metformin Hcl | Metformin Hcl | 242 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 57 |
| Simvastatin | Simvastatin | 192 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 54 |
| Allopurinol | Allopurinol | 180 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 43 |
| Losartan Potassium | Losartan Potassium | 164 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 45 |
| Eliquis | Apixaban | 106 | 28 |
| Spironolactone | Spironolactone | 104 | 23 |
| Sertraline Hcl | Sertraline Hcl | 96 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 25 |
| Furosemide | Furosemide | 85 | 26 |
| Mirtazapine | Mirtazapine | 85 | 13 |
| Carvedilol | Carvedilol | 83 | 26 |
| Ezetimibe | Ezetimibe | 83 | 24 |
| Lorazepam | Lorazepam | 80 | 34 |
| Gabapentin | Gabapentin | 79 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 22 |
| Alprazolam | Alprazolam | 78 | 26 |
| Warfarin Sodium | Warfarin Sodium | 77 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 15 |
| Azithromycin | Azithromycin | 75 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 22 |
| Finasteride | Finasteride | 71 | 16 |
| Potassium Chloride | Potassium Chloride | 71 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 53 |
| Prednisone | Prednisone | 61 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 16 |
| Metformin Hcl Er | Metformin Hcl | 56 | 18 |
| Donepezil Hcl | Donepezil Hcl | 55 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 18 |
| Montelukast Sodium | Montelukast Sodium | 55 | 16 |
| Memantine Hcl | Memantine Hcl | 54 | 11 |
| Cephalexin | Cephalexin | 53 | 38 |
| Rybelsus | Semaglutide | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 29 |
| Repaglinide | Repaglinide | 47 | 15 |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Naproxen | Naproxen | 46 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 29 |
| Dutasteride | Dutasteride | 42 | suppressed |
| Glipizide Er | Glipizide | 41 | 12 |
| Tramadol Hcl | Tramadol Hcl | 41 | 16 |
| Atenolol | Atenolol | 40 | 11 |
| Celecoxib | Celecoxib | 39 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Meloxicam | Meloxicam | 37 | 17 |
| Ozempic | Semaglutide | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 23 |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 34 | 13 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | 12 |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 14 |
| Famotidine | Famotidine | 33 | 13 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 17 |
| Ramipril | Ramipril | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 14 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Diazepam | Diazepam | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Dupixent Syringe | Dupilumab | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $470.47 · 23 records | Radius Health, Inc. | AIRSUPRA, Flector, JARDIANCE, Kerendia, Korlym, Licart, Ozempic, QULIPTA, REXULTI, Rybelsus, SPRAVATO, The Cologuard Plus Collection Kit, Tirosint, Tymlos, UBRELVY, VOQUEZNA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error